New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
08:52 EDTPTCTPTC Therapeutics price target raised to $43 from $34 at Roth Capital
Roth Capital increased its price target on PTC as the firm thinks that, based on recent favorable developments, the company's spinal muscular atrophy program is gaining steam. Roth believes that the compounds identified by PTC can be expanded to other neuro-muscular disorders. Roth reiterates a Buy rating on the stock.
News For PTCT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
06:38 EDTPTCTBioMarin price target raised to $163 from $147 at Piper Jaffray
Subscribe for More Information
July 15, 2015
16:28 EDTPTCTOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
12:18 EDTPTCTOn The Fly: Top stock stories at midday
Subscribe for More Information
06:45 EDTPTCTJPMorgan upgrades PTC Therapeutics with $100 target ahead of data
JPMorgan analyst Anupam Rama upgraded PTC Therapeutics (PTCT) to Overweight from Neutral citing an attractive risk/reward profile into the phase 3 results for Translarna in non-sense mutation Duchenne Muscular Dystrophy. The data are expected in Q4. Rama believes the study is designed for success and raised the firm's probability of success to 80%. PTC shares are off down 37% since the mid-March highs when takeout speculation was a key driver of appreciation, Rama tells investors this morning in a research note. The analyst raised PTC's price target to $100 from $74. Shares of PTC closed yesterday up $1.30 to $48.94.
06:44 EDTPTCTPTC Therapeutics upgraded to Overweight from Neutral at JPMorgan
Price target raised to $100 from $74.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use